Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease June 26, 2026 View Press Release
Viridian Therapeutics to Participate in Upcoming June Investor Conferences May 27, 2026 View Press Release
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million May 6, 2026 View Press Release
